Biotech Values

[mcbio]

Note that PLX is going for inhaled formulation and they will know the results from KMDA's phase II/III of inhaled AAT in the same indication by early 2014. Interesting also since Kamada has an orphan drug designation in both EU and US.

Are you suggesting PLX may not have a path forward in AAT if KMDA is successful? I saw a prior post from last year where you indicated you didn't think PLX could work around AMGN's patents on its anti-TNF drug.

In general, are you a fan of PLX risk-reward here?